1. Home
  2. RGEN vs CWAN Comparison

RGEN vs CWAN Comparison

Compare RGEN & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • CWAN
  • Stock Information
  • Founded
  • RGEN 1981
  • CWAN 2004
  • Country
  • RGEN United States
  • CWAN United States
  • Employees
  • RGEN N/A
  • CWAN N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • CWAN Computer Software: Prepackaged Software
  • Sector
  • RGEN Health Care
  • CWAN Technology
  • Exchange
  • RGEN Nasdaq
  • CWAN Nasdaq
  • Market Cap
  • RGEN 8.0B
  • CWAN 6.1B
  • IPO Year
  • RGEN N/A
  • CWAN 2021
  • Fundamental
  • Price
  • RGEN $131.04
  • CWAN $21.77
  • Analyst Decision
  • RGEN Buy
  • CWAN Buy
  • Analyst Count
  • RGEN 11
  • CWAN 10
  • Target Price
  • RGEN $169.33
  • CWAN $31.50
  • AVG Volume (30 Days)
  • RGEN 691.4K
  • CWAN 4.2M
  • Earning Date
  • RGEN 07-29-2025
  • CWAN 07-30-2025
  • Dividend Yield
  • RGEN N/A
  • CWAN N/A
  • EPS Growth
  • RGEN N/A
  • CWAN N/A
  • EPS
  • RGEN N/A
  • CWAN 1.71
  • Revenue
  • RGEN $650,429,000.00
  • CWAN $475,948,000.00
  • Revenue This Year
  • RGEN $13.93
  • CWAN $63.43
  • Revenue Next Year
  • RGEN $14.35
  • CWAN $29.94
  • P/E Ratio
  • RGEN N/A
  • CWAN $12.75
  • Revenue Growth
  • RGEN 4.88
  • CWAN 23.21
  • 52 Week Low
  • RGEN $102.97
  • CWAN $17.94
  • 52 Week High
  • RGEN $182.52
  • CWAN $35.71
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 57.17
  • CWAN 44.69
  • Support Level
  • RGEN $123.34
  • CWAN $21.39
  • Resistance Level
  • RGEN $129.11
  • CWAN $22.92
  • Average True Range (ATR)
  • RGEN 4.31
  • CWAN 0.65
  • MACD
  • RGEN 1.06
  • CWAN 0.06
  • Stochastic Oscillator
  • RGEN 77.06
  • CWAN 45.33

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About CWAN Clearwater Analytics Holdings Inc.

Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.

Share on Social Networks: